Brief overview of child and adolescent psychopharmacotherapy

1. H osák L, Hrdlička M. Psychiatrie a pedopsychiatrie. Praha: Karolinum Press 2016: 393–402.

2. U hrová T, Roth J, et al. Neuropsychiatrie. Praha: Maxdorf 2020: 940–941.

3. H ort V, Malá E. Dětská a adolescentní psychiatrie. Praha: Portál 2008: 421–454.

4. S choretsantis G, Paulzen M, Unterecker S, et al. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World J Biol Psychiatry 2018; 19(3): 162–174.

5. S adock BJ, Sadock VA, et al. Kaplan and Sadock’s Synopsis of Psychiatry. 10. vyd. New York: Wolters Kluwer 2007: 1318–1326.

6. N inan A, Stewart SL, Theall LA, et al. Adverse effects of psychotropic medications in children: predictive factors. J Can Acad Child Adolesc Psychiatry 2014; 23(3): 218–225.

7. S ikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004; 29(1): 133–145.

8. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 2006; 29(4): 303–319.

9. Moon YE. Paradoxical reaction to midazolam in children. Korean J Anesthesiol 2013; 65(1): 2–3. doi: 10.4097/kjae.2013. 65. 1.2

10. WHO. Adolescent mental health. Dostupné na: https:// www.who.int/news-room/fact-sheets/detail/adolescent-mental-health.

11. Ž aludek A, David J, Marx D. Časná identifikace sebevražedného chování u dětí a spolupráce mezi pediatrem a psychiatrem. Pediatr praxi 2020; 21(5): 320–322.

12. M ohr P, Kopeček M, Brunovský M, Páleníček T. Klinická psychofarmakologie. Praha: Maxdorf 2017.